Evaluation of the Efficacy and Safety of the Combination of Gemcitabine and Nedaplatin for Elderly Patients with Advanced Non-Small-Cell Lung Cancer
The study aimed to retrospectively assess the safety and efficacy of the combination of gemcitabine and nedaplatin in elderly patients with advanced non-small-cell lung cancer (NSCLC). Patients age greater than 75 years with previously untreated NSCLC who underwent chemotherapy consisting of gemcitabine (800 mg/m2 on days 1 and 8) and nedaplatin (80 mg/m2 on day 1) every 3 week were retrospectively analysed. The results showed that 35 patients, 28 were men and 7 were women, with a mean age of 78 years (range 75-87); 10 patients had stage IIIB disease and 25 patients had stage IV disease. The overall response rate was 45.7%. The median survival time was 14 months (range 3-44). Grade 3-4 toxicities included neutropenia in 74.3%, thrombocytopenia in 48.6%, anaemia in 34.3%, hepatic dysfunction in 11.4%, and infection in 2.9%. There were no treatment related deaths. There were no differences in response rate and survival between patients aged 75-79 years and patients greater than 80 years, although grade 3-4 thrombocytopenia and anaemia were significantly more frequent in patients greater than 80 years. The authors concluded that the combination of gemcitabine and nedaplatin was effective and well tolerated for selected elderly patients with advanced NSCLC.